Akebia Therapeutics, Inc.
Company Stats
- Market Cap
- $254.9M
- as of Sep 30, 2026
- Enterprise Value
- $122.5M
- Shares Outstanding
- 277.1M
- Free Float
- 93.4%
Income Statement
- Revenue
- $236.2M
- Operating Income
- $23.5M
- Net Income
- -$5.3M
- EBITDA
- $24.8M
- Revenue Growth, 3Y
- -6.9%
- FCF Margin, 3Y Avg
- -2.9%
- FCF Margin, Worst Year
- -25.4%
Cash Flow
- Free Cash Flow
- $67.7M
- FCF Yield
- 26.6%
- Owner FCF Yield
- 22.1%
Balance Sheet
- Cash & Equivalents
- $184.8M
- Total Debt
- $52.4M
- Net Cash
- $132.4M
- EV / EBITDA
- 4.95x
Returns & Capital
- SBC, 3Y Avg
- $9.5M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $236.2M | $67.7M | 28.7% |
| FY2024 | $160.2M | -$40.7M | -25.4% |
| FY2023 | $194.6M | -$23.4M | -12.0% |
| FY2022 | $292.5M | -$73.3M | -25.1% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 31, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges